For instance, anti-EGFR agents are more effective in inducing CRC cytoreduction than do anti-VEGF agents in patients with the wild-type KRAS gene and mCRC, which means fewer patients exhibit a PD after using anti-EGFR agents as the first-line treatment (77, 78). The gene discussed is VEGFA; the disease is colorectal carcinoma.